Neuroaid

Neuroaid (also NeuroAiD, MLC 601, or MLC 901) is a claimed treatment for stroke sold by Moleac Pte Ltd, a biopharmaceutical company in Singapore. There are two versions: Neuroaid (MLC601) and Neuroaid II (MLC901), with differing blends of ingredients. The ingredients total 14 for both, with nine derived from plants and five from animals. Neuroaid (also NeuroAiD, MLC 601, or MLC 901) is a claimed treatment for stroke sold by Moleac Pte Ltd, a biopharmaceutical company in Singapore. There are two versions: Neuroaid (MLC601) and Neuroaid II (MLC901), with differing blends of ingredients. The ingredients total 14 for both, with nine derived from plants and five from animals. In vitro and in vivo results show that Neuroaid makes cells more resistant against glutamate aggression, increases neurite outgrowth and connectivity as well as reduces the infarct volume. Recent studies have shown stronger evidence that Neuroaid increases patient outcomes post-stroke as well as after a traumatic brain injury has occurred. Research to support its safety and use have shown its effectiveness in both animals and humans.MLC901 (NeuroAid II) has been shown to have significant effects on patient healing after a concussion. A 2018 publication provided class I/II evidence that, for patients with mild to moderate TBI, 6 months of MLC901 improved cognitive functioning. There is weak evidence that Neuroaid (MLC 601) might have some benefit for post-stroke recovery when used in addition to standard treatment.